H Nida Sen1, Susan Vitale2, Sapna S Gangaputra3, Robert B Nussenblatt2, Teresa L Liesegang4, Grace A Levy-Clarke5, James T Rosenbaum6, Eric B Suhler7, Jennifer E Thorne8, C Stephen Foster9, Douglas A Jabs10, John H Kempen11. 1. Laboratory of Immunology, National Eye Institute, Bethesda, Maryland. Electronic address: senh@nei.nih.gov. 2. Laboratory of Immunology, National Eye Institute, Bethesda, Maryland. 3. Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, Wisconsin. 4. Department of Ophthalmology, Oregon Health & Science University, Portland, Oregon. 5. Laboratory of Immunology, National Eye Institute, Bethesda, Maryland; Tampa Bay Uveitis Center, Tampa, Florida. 6. Department of Ophthalmology, Oregon Health & Science University, Portland, Oregon; Department of Medicine, Oregon Health & Science University, Portland, Oregon. 7. Department of Ophthalmology, Oregon Health & Science University, Portland, Oregon; Veterans' Affairs Medical Center, Portland, Oregon. 8. Department of Ophthalmology, The Johns Hopkins University, Baltimore, Maryland; Department of Epidemiology, The Johns Hopkins University, Baltimore, Maryland. 9. Massachusetts Eye Research and Surgery Institute, Cambridge, Massachusetts; Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts. 10. Department of Epidemiology, Center for Clinical Trials, the Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland; Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York; Department Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. 11. Department of Ophthalmology, The University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, The University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Department of Biostatistics and Epidemiology, The University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Abstract
PURPOSE: To evaluate the benefits and complications of periocular depot corticosteroid injections in patients with ocular inflammatory disorders. DESIGN: Multicenter, retrospective cohort study. PARTICIPANTS: A total of 914 patients (1192 eyes) who had received ≥ 1 periocular corticosteroid injection at 5 tertiary uveitis clinics in the United States. METHODS: Patients were identified from the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Demographic and clinical characteristics were obtained at every visit via medical record review by trained reviewers. MAIN OUTCOME MEASURES: Control of inflammation, improvement of visual acuity (VA) to ≥ 20/40, improvement of VA loss attributed to macular edema (ME), incident cataract affecting VA, cataract surgery, ocular hypertension, and glaucoma surgery. RESULTS: Among 914 patients (1192 eyes) who received ≥ 1 periocular injection during follow-up, 286 (31.3%) were classified as having anterior uveitis, 303 (33.3%) as intermediate uveitis, and 324 (35.4%) as posterior or panuveitis. Cumulatively by ≤ 6 months, 72.7% (95% CI, 69.1-76.3) of the eyes achieved complete control of inflammation and 49.7% (95% CI, 45.5-54.1) showed an improvement in VA from <20/40 to ≥ 20/40. Among the subset with VA <20/40 attributed to ME, 33.1% (95% CI, 25.2-42.7) improved to ≥ 20/40. By 12 months, the cumulative incidence of ≥ 1 visits with an intraocular pressure of ≥ 24 mmHg and ≥ 30 mmHg was 34.0% (95% CI, 24.8-45.4) and 15.0% (95% CI, 11.8-19.1) respectively; glaucoma surgery was performed in 2.4% of eyes (95% CI, 1.4-3.9). Within 12 months, among phakic eyes initially ≥ 20/40, the incidence of a reduction in VA to <20/40 attributed to cataract was 20.2% (95% CI, 15.9-25.6); cataract surgery was performed within 12 months in 13.8% of the initially phakic eyes (95% CI, 11.1-17.2). CONCLUSIONS: Periocular injections were effective in treating active intraocular inflammation and in improving reduced VA attributed to ME in a majority of patients. The response pattern was similar across anatomic locations of uveitis. Overall, VA improved in one half of the patients at some point within 6 months. However, cataract and ocular hypertension occurred in a substantial minority.
PURPOSE: To evaluate the benefits and complications of periocular depot corticosteroid injections in patients with ocular inflammatory disorders. DESIGN: Multicenter, retrospective cohort study. PARTICIPANTS: A total of 914 patients (1192 eyes) who had received ≥ 1 periocular corticosteroid injection at 5 tertiary uveitis clinics in the United States. METHODS:Patients were identified from the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Demographic and clinical characteristics were obtained at every visit via medical record review by trained reviewers. MAIN OUTCOME MEASURES: Control of inflammation, improvement of visual acuity (VA) to ≥ 20/40, improvement of VA loss attributed to macular edema (ME), incident cataract affecting VA, cataract surgery, ocular hypertension, and glaucoma surgery. RESULTS: Among 914 patients (1192 eyes) who received ≥ 1 periocular injection during follow-up, 286 (31.3%) were classified as having anterior uveitis, 303 (33.3%) as intermediate uveitis, and 324 (35.4%) as posterior or panuveitis. Cumulatively by ≤ 6 months, 72.7% (95% CI, 69.1-76.3) of the eyes achieved complete control of inflammation and 49.7% (95% CI, 45.5-54.1) showed an improvement in VA from <20/40 to ≥ 20/40. Among the subset with VA <20/40 attributed to ME, 33.1% (95% CI, 25.2-42.7) improved to ≥ 20/40. By 12 months, the cumulative incidence of ≥ 1 visits with an intraocular pressure of ≥ 24 mmHg and ≥ 30 mmHg was 34.0% (95% CI, 24.8-45.4) and 15.0% (95% CI, 11.8-19.1) respectively; glaucoma surgery was performed in 2.4% of eyes (95% CI, 1.4-3.9). Within 12 months, among phakic eyes initially ≥ 20/40, the incidence of a reduction in VA to <20/40 attributed to cataract was 20.2% (95% CI, 15.9-25.6); cataract surgery was performed within 12 months in 13.8% of the initially phakic eyes (95% CI, 11.1-17.2). CONCLUSIONS: Periocular injections were effective in treating active intraocular inflammation and in improving reduced VA attributed to ME in a majority of patients. The response pattern was similar across anatomic locations of uveitis. Overall, VA improved in one half of the patients at some point within 6 months. However, cataract and ocular hypertension occurred in a substantial minority.
Authors: Ahmed Sallam; Simon R J Taylor; Zohar Habot-Wilner; Mostafa Elgohary; Helen H Do; Peter McCluskey; Sue Lightman Journal: Acta Ophthalmol Date: 2011-09-13 Impact factor: 3.761
Authors: John H Kempen; Michael M Altaweel; Janet T Holbrook; Douglas A Jabs; Thomas A Louis; Elizabeth A Sugar; Jennifer E Thorne Journal: Ophthalmology Date: 2011-08-15 Impact factor: 12.079
Authors: Sherveen S Salek; Henry A Leder; Nicholas J Butler; Theresa J Gan; James P Dunn; Jennifer E Thorne Journal: Ocul Immunol Inflamm Date: 2013-04-25 Impact factor: 3.070
Authors: Sirichai Pasadhika; John H Kempen; Craig W Newcomb; Teresa L Liesegang; Siddharth S Pujari; James T Rosenbaum; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; Eric B Suhler Journal: Am J Ophthalmol Date: 2009-07-01 Impact factor: 5.258
Authors: Zohar Habot-Wilner; Ahmed Sallam; Patricio A Pacheco; Helen H Do; Peter McCluskey; Sue Lightman Journal: Eur J Ophthalmol Date: 2011 Impact factor: 2.597
Authors: Sapna Gangaputra; Craig W Newcomb; Teresa L Liesegang; R Oktay Kaçmaz; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; John H Kempen Journal: Ophthalmology Date: 2009-09-12 Impact factor: 12.079
Authors: Jasmine R Elison; Jessica E Weinstein; Kristopher G Sheets; Cornelius E Regan; Jennifer J Lentz; Maria Reinoso; William C Gordon; Nicolas G Bazan Journal: Curr Eye Res Date: 2018-04-11 Impact factor: 2.424
Authors: John H Kempen; Mark L Van Natta; Michael M Altaweel; James P Dunn; Douglas A Jabs; Susan L Lightman; Jennifer E Thorne; Janet T Holbrook Journal: Am J Ophthalmol Date: 2015-09-18 Impact factor: 5.258